Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients

Inclusion criteria: * Friedreich's ataxia patients completing core study SNT-III-002 (NCT00537680) and presenting at Week 24 (Visit 5) of that study * Body weight ≥ 25kg/55 lbs * Negative urine pregnancy test * Patients who in the opinion of the investigator are able to comply with the requirements of this study Exclusion criteria: * Adverse events during the course of SNT-III-002(NCT00537680)which in the opinion of the investigator are attributable to idebenone and preclude further treatment with idebenone * Clinically significant abnormalities of clinical hematology or biochemistry including, but not limited to, elevations greater than 2 times the upper limit of normal of AST, ALT or creatinine * Treatment with coenzyme Q10, vitamin E (if taken at a dose 5 times above the daily requirement) or other sources of idebenone within the past month * Parallel participation in another clinical drug trial * Past or present history of abuse of drugs or alcohol * Pregnancy or breast-feeding